What You Should Know:
– Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential earn-out and milestone payments.
– The strategic acquisition strengthens Lantheus’ position in the radiopharmaceutical market and establishes a commercial presence in the Alzheimer’s disease (AD) space.
Life Molecular Imaging Background
Life Molecular Imaging, a subsidiary of Life Healthcare Group Holdings Ltd, is dedicated to developing innovative Positron Emission Tomography (PET) radiopharmaceutical diagnostics. The acquisition brings several key assets to Lantheus, including Neuraceq® (florbetaben F18 injection), a globally approved diagnostic agent for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.
Strategic and Financial Benefits
This acquisition offers compelling strategic and financial benefits for Lantheus:
- Establishes AD Franchise: Provides immediate commercial capabilities and infrastructure in the AD market, including a manufacturing network and go-to-market experience.
- Expands Growth Profile: Adds Neuraceq®, a globally marketed radioactive agent for diagnosing cognitive impairments, accelerating Lantheus’ revenue growth.
- Enhances R&D Capabilities: Brings high-caliber research and development resources to strengthen Lantheus’ pipeline.
- Complements Existing Pipeline: Adds complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs.
- Accretive to Earnings: Expected to be accretive to Lantheus’ Adjusted Earnings Per Share within 12 months of closing.
“This acquisition aligns with our strategy to drive long-term growth and value creation by investing in high-potential, complementary assets and R&D capabilities to strengthen our radiopharmaceutical leadership,” said Brian Markison, CEO of Lantheus. “This is a natural extension of our existing RM2 partnership, and we are ideally equipped to collectively grow Neuraceq and advance Life Molecular’s diverse radiopharmaceutical assets. We are excited to welcome their exceptionally talented team, whose expertise will further enhance our capabilities in the development and commercialization of innovative radiodiagnostic solutions. With our combined resources and financial strength, we are well-positioned to deliver a meaningful impact for patients and clinicians worldwide.”Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential earn-out and milestone payments.
